ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 2,000 shares of the business’s stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $99.36, for a total transaction of $198,720.00. Following the transaction, the chief financial officer now owns 71,072 shares in the company, valued at $7,061,713.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Brett Sandercock also recently made the following trade(s):
- On Thursday, March 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $98.53, for a total transaction of $197,060.00.
- On Thursday, February 15th, Brett Sandercock sold 2,000 shares of ResMed stock. The stock was sold at an average price of $93.42, for a total transaction of $186,840.00.
- On Thursday, February 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The shares were sold at an average price of $100.13, for a total transaction of $125,162.50.
Shares of RMD opened at $101.17 on Thursday. The stock has a market capitalization of $14,249.83, a P/E ratio of 35.88 and a beta of 0.90. ResMed Inc. has a 52 week low of $67.04 and a 52 week high of $104.78.
ResMed (NYSE:RMD) last posted its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.22. The firm had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 EPS. equities analysts forecast that ResMed Inc. will post 3.38 earnings per share for the current year.
A number of brokerages recently commented on RMD. William Blair reiterated an “outperform” rating on shares of ResMed in a research note on Monday. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research note on Friday, February 2nd. Citigroup lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 4th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Wednesday, March 7th. Finally, ValuEngine upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $74.83.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in ResMed in the 3rd quarter valued at about $113,000. Calton & Associates Inc. bought a new stake in ResMed in the 4th quarter valued at about $115,000. Conning Inc. bought a new stake in ResMed in the 4th quarter valued at about $203,000. Commerzbank Aktiengesellschaft FI bought a new stake in ResMed in the 4th quarter valued at about $206,000. Finally, Dowling & Yahnke LLC bought a new stake in ResMed in the 4th quarter valued at about $208,000. 62.41% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/19/brett-sandercock-sells-2000-shares-of-resmed-inc-rmd-stock.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.